Engineered Adoptive Cell Therapies

Patients eligible for clinical trials with ACTengine® product candidates have a portion of their white blood cells collected using a well-established process called leukapheresis, a procedure in which a fraction of the white blood cells of a patient is extracted from their peripheral blood. These white blood cells are transferred to a manufacturing facility where peripheral blood mononuclear cells (“PBMCs”), which are a subset of white blood cells, are isolated from the leukapheresis product. PBMCs or a selected subset of T cells (e.g. CD8+ T cells) is the starting point of the ACTengine® manufacturing process. T cells contained within PBMCs are activated and subsequently mixed with a lentiviral vector which introduces the genes encoding the target specific TCR into the T cells. These genetically engineered T cells are expanded in the presence of a cytokine mixture. All in all, the total ACTengine® manufacturing time is 7-10 days (IMA201/202) or 6 days (IMA203). The ex vivo expanded T cells are concentrated and frozen before undergoing quality control release testing. The resulting cell product can be stored frozen long-term until the patient is ready to receive the infusion.

Enhancement Strategies

Immatics’ latest proprietary ACTengine® manufacturing processes are designed to generate cell product candidates within a short 6-day manufacturing window and deliver highly proliferative T cells, with the capability to infiltrate the patient’s tumor and function in a challenging solid tumor microenvironment. Immatics is actively investigating multiple next-generation enhancement strategies to render T cells even more potent to combat solid tumors. For advanced-stage clinical trials and commercial supply, manufacturing processes are planned to be further optimized to ensure a robust manufacturing capability incorporating functionally closed and automated manufacturing systems as well as the use of serum free, chemically defined media.

Immatics’ T cell products are manufactured by Immatics personnel at the UTHealth Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in a state-of-the-art cGMP facility exclusively used by Immatics in Houston, Texas.


A TCER™ consists of three distinct elements:

Immatics’ TCER™ molecules can be produced and purified utilizing established processes to manufacture antibodies.

Immatics’ TCER™ scaffold is the result of a campaign to engineer and evaluate various molecular scaffolds incorporating binding domains derived from affinity and stability enhanced TCRs and from T cell recruiting antibodies, respectively. The TCER™ architecture, in Immatics’ in vitro testing, proved to be superior to other tested scaffolds with respect to preclinical efficacy, stability and physio-chemical properties, so called “developability”. TCER™ molecules can readily be expressed in CHO-cells with titers comparable to antibody-based biologics. The TCER™ protein can be purified using common chromatographic techniques and size-exclusion-chromatography, facilitating the cGMP-compliant manufacturing in established plants.

The manufacturing development phase of IMA401 TCER™ is ongoing and includes cell line development, upstream and downstream process development, GMP production, fill and finish, release testing, storage and stability testing.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.